HFM
BBIO icon

Harvest Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Harvest Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70K Sell
938
-3,038
-76% -$220K ﹤0.01% 324
2025
Q4 		$304K Buy
3,976
+3,321
+507% +$218K 0.01% 318
2025
Q3 		$34K Buy
+655
New +$31.9K ﹤0.01% 456

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harvest Fund Management's BBIO Position: Q1 2026 in Review

Harvest Fund Management reduced its BridgeBio Pharma (BBIO) stake by 76% in Q1 2026, selling an estimated $220K and leaving 938 shares worth $70K. The position accounts for ﹤0.01% of the portfolio, ranked #324.

Harvest Fund Management first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $304K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Harvest Fund Management held 938 shares of BridgeBio Pharma worth $70K as of Q1 2026.
  • Harvest Fund Management sold 3,038 BridgeBio Pharma shares in Q1 2026, an estimated $220K.
  • BridgeBio Pharma made up ﹤0.01% of Harvest Fund Management's portfolio in Q1 2026, its #324 holding.
  • Harvest Fund Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • Harvest Fund Management's BridgeBio Pharma position peaked at $304K in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Harvest Fund Management's 13F filing for Q1 2026, filed 14 May 2026.